Demographic data of 19 patients with polymyositis and dermatomyositis.
| Characteristics | All Patients, n = 19, Median (Q1–Q3) | Exercise Group, n = 10, Median (Q1–Q3) | Control Group, n = 9, Median (Q1–Q3) |
|---|---|---|---|
| Age, yrs | 60.0 (52.0–67.0) | 56.5 (44.0–62.0) | 62.0 (54.0–70.0) |
| Diagnosis, PM/DM | 10/9 | 5/5 | 5/4 |
| Sex, female/male, n | 14/5 | 9/1 | 5/4 |
| Diagnosis duration, mo | 3.0 (2.0–3.0) | 2.0 (1.5–3.0) | 3.0 (2.5–3.0) |
| Serum CPK at diagnosis, μcat/l | 23 (15.0–60.0) | 27.4 (15.0– > 76.8) | 21.9 (15.1–42.4) |
| Serum CPK at baseline, μcat/l | 1.9 (0.6–5.7) | 2.1 (0.5–4.7) | 1.9 (0.8–5.7) |
| Prednisolone dose at diagnosis, mg/day | 60 (45.0–60.0) | 50.0 (50.0–60.0) | 60.0 (40.5–60.0) |
| Prednisolone dose at baseline, mg/day | 40 (30.0–60.0) | 40.0 (25.0–40.0) | 40.0 (40.0–50.0) |
| DMARD | |||
| AZA/MTX/CYC, n | 13/3/2 | 9/1/10 | 4/2/2 |
| Muscle function at baseline | |||
| FI, 0–64 | 42 (30.0–48.5) | 39.8 (24.0–48.5) | 46.5 (40.0–48.0) |
| Aerobic capacity, ml × kg × min | 25.01 (18.51–26.57)2 | 23.59 (18.51–25.06)1 | 26.47 (21.73–28.43)1 |
| Perceived health at baseline | |||
| NHP Energy, 0–100 | 24.0 (0.0–100.0)4 | 80.4 (30.4–100.0)2 | 0.0 (0.0–24.0)2 |
| NHP Pain, 0–100 | 9.0 (0.0–20.2)4 | 19.8 (14.2–28.6)2 | 0.0 (0.0–9.0)2 |
| NHP Sleep, 0–100 | 21.7 (12.6–39.8)4 | 34.6 (18.9–42.3)2 | 12.6 (0.0–34.3)2 |
| NHP Social, 0–100 | 0.0 (0.0–22.0)4 | 0.0 (0.0–32.1)2 | 0.0 (0.0–16.0)2 |
| NHP Emotional, 0–100 | 33.9 (7.2–61.0)4 | 50.5 (39.0–72.7)2 | 7.22 (0.0–16.2)2 |
| NHP Physical, 0–100 | 10.6 (0.0–21.4)4 | 16.5 (10.7–33.7)2 | 0.0 (0.0–10.6)2 |
Q1–Q3: lower to upper quartile; PM: polymyositis; DM: dermatomyositis; CPK: creatine phosphokinase; DMARD: disease-modifying antirheumatic drug; AZA: azathioprine; MTX: methotrexate; CYC: cyclophosphamide; FI: Functional Index; NHP: Nottingham Health Profile;
↵1 = 1 missing case;
↵2 = 2 missing cases;
↵4 = 4 missing cases.